scholarly journals CONTENT-ANALYSIS OF THE PHARMACEUTICAL MARKET OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN GROUPS OF ACETIC ACID DERIVATIVES IN THE KYRGYZ REPUBLIC

2020 ◽  
Vol 22 (1) ◽  
pp. 74-81
Author(s):  
Dinara Ermekova ◽  
◽  
Isabek Ismailov ◽  

Objective: To segment the pharmaceutical market of non-steroidal anti-inflammatory drugs (NSAIDs) of the derivatives groups of acetic acid in the Kyrgyz Republic. Methods: The database of the State Registry of Medicines registered and approved for Medical use in Kyrgyzstan, the Department of Drugs Security and Medical Engineering of the Ministry of Health of the Kyrgyz Republic is used for analysis. Results: Analysis showed that the leaders of the pharmaceutical market in Kyrgyzstan the number of registered medicines (M) under the trade names are Medical Drugs (MD) with international generic name: diclofenac, ketorolac, indomethacin. It has been established that there are 99 trade names of NSAIDs of the groups of acetic acid derivatives in the Kyrgyz pharmaceutical market. The largest part of the range consists of diclofenac (M01AB05), represented by 62 trade names MD (62.6%), and ketorolac (M01AB15), represented by 20 trade names MD (20.2%). In the pharmaceutical market of Kyrgyzstan are NSAIDs from the groups of acetic acid derivatives from 15 countries, of which 21.1% of MDs are produced by neighboring countries, and 73.3% – in far countries. Conducted studies have revealed that the structure of the range of NSAIDs groups of acetic acid derivatives is dominated by soft medicinal forms, which making up 37.4%. A comparative analysis of the composition of MD by the number of active substances revealed that 92.9% of NSAIDs of the groups of acetic acid derivatives are monodrugs. Based on the analysis of the price segmentation of NSAIDs of the groups of acetic acid derivatives, most of the drugs are in the low-price segment. Conclusions: A sufficient assortment saturation of the pharmaceutical market of Kyrgyzstan NSAIDs groups of acetic acid derivatives has been revealed. The pharmaceutical market of the Kyrgyz Republic is dominated by monocomponent NSAIDs in the form of soft medicinal forms produced in foreign countries. Only 7 MDs from this group are in the high-price range, making the remaining drugs financially available to consumers. Keywords: NSAIDs, indomethacin, diclofenac, etodolac, ketorolac, aceclophenac.

2019 ◽  
pp. 41-51
Author(s):  
L. V. Iakovlieva ◽  
A. A. Titova

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) are groups of different chemical structures of drugs (derivatives of acids) that are widely used in clinical practice. More than three million people in the world take NSAIDs every day. The aim of the study – аnalysis of the range and target characteristics of nonsteroidal anti-inflammatory drugs in the Ukrainian pharmaceutical market during 2014–2018. Nonsteroidal anti-inflammatory drugs, presented on the pharmaceutical market of Ukraine for 2014–2017, were selected as research objects. The research used retail prices, according to the «Pharmstandard» system of the «Morion» company. NSAIDs in Ukraine during 2014–2018 were represented from 302 to 419 TN based on 32 INN. Diclofenac was also represented by the largest number of trade names, due to its distinct efficacy, less toxicity among the most effective drugs and the low cost of domestic generic drugs. Fewer TN than Diclofenac but more than the bulk of NSAIDs in the market were presented by the following INNs – meloxicam, ibuprofen, nimesulide and a combination of glucosamine with chondroitin sulfate. A large selection of NSAIDs has been identified in the pharmaceutical market of Ukraine. Imported Nonsteroidal anti-inflammatory drugs are more represented. These drugs have a wide range of prices that allow you to optimize your treatment costs. The prices of NSAIDs for researched period had increase. The reason can be in conditions of political and socio-economic crisis in the country


1983 ◽  
Vol 33 (2) ◽  
pp. 447-454 ◽  
Author(s):  
Hiroshi TANAKA ◽  
Katsuichi SHUTO ◽  
Nobuhiro NAKAMIZO

1983 ◽  
Vol 33 (2) ◽  
pp. 447-454
Author(s):  
Hiroshi TANAKA ◽  
Katsuichi SHUTO ◽  
Nobuhiro NAKAMIZO

1982 ◽  
Vol 32 ◽  
pp. 94
Author(s):  
Hiroshi Tanaka ◽  
Katsuichi Shuto ◽  
Nobuhiro Nakamizo

2018 ◽  
Vol 65 (1) ◽  
pp. 10-14
Author(s):  
A. A. Kotvitska ◽  
V. H. Kostiuk

Abstract The aim of our analysis is the estimation of non-steroid anti-inflammatory drugs (NSAID) competitiveness level, calculation of capacity, share and saturation of studied segment of market that allow to improve the competitive strategies of pharmaceutical manufacturing enterprises. MATERIALS AND METHODS: According to the results of content-analysis of foreign and native economic literature, we elaborated the methodology of estimation of NSAID competitive positions that consists of six main stages. The offered model of estimation of competitiveness of the studied group of medicines is based on the construction of competition map of medicines on the example of non-selective NSAID as the largest group by the number of presented trade names (TN) using the calculation of market share of medicines for 2015-2016 and dynamics of its growth. RESULTS: The results of NSAID TN distribution in groups according to the market share volume testify that only 8 TN of medicines among 74 are the leaders of market and 10 TN are characterized with strong competitive position. At the same time 51 NSAID TN are outsiders and 5 TN have weak competitive position. The results of NSAID TN distribution in groups according to the change of their competitive position allow state that 16 TN among 74 have fast worsening competitive position, 43 TN belong to the group with worsening competitive position and only 5 TN has competitive position, characterized by fast improvement. CONCLUSION: The analysis of position, occupied by NSAID TN in matrix, demonstrated that 8 TM of medicines are the leaders of the market. At the same time 51 medicines TN are outsiders. The results of research demonstrated that 59 NSAID TN are characterized with worsening and fast worsening competitive positions.


2020 ◽  
Author(s):  
Tilahun Beyene

BACKGROUND Diclofenac is a Non-steroid Anti-inflammatory drug (NSAID) derived from non-steroidal phenylacetic acid. Diclofenac is a benzene acetic acid derivative used to treat the pain and swelling associated with rheumatic disorders since 1974. It is one of the most widely used non-steroidal anti-inflammatory Drugs (NSAIDs) in the world. A few reports have demonstrated that non-steroidal anti-inflammatory drugs exerted embryo toxicity and teratogenicity among experimental animals but there is no clear evidence of the effect in humans. OBJECTIVE To perform a systematic review on the effect of Diclofenac exposure during Pregnancy on mother and fetus. METHODS This systematic review was conducted in accordance with the JBI methodology for systematic review of effectiveness evidence. A three-step search strategy used in this review. Databases searched included Pub Med, Medline Scopus, Embase, cinihal, Google, different Universities repositories and Google scholar. Titles and abstracts were then screened by two independent reviewers for assessment against the inclusion criteria for the review. Eligible studies were critically appraised by two independent reviewers at the study level. Appraisal was occurred at the outcome level for methodological quality in the review using standardized critical appraisal instruments from the Joanna Briggs Institute (JBI) for observational studies. The data extracted from the studies include specific details about the populations, study methods, interventions, and outcomes of significance to the review objective indicate the specific details. Statistical pooling was not possible due to outcome and nature of data. So, that the findings were presented in narrative form. RESULTS Three relevant articles (two cohort and a nested case control studies) were identified with a total of 1,490,679 participants. Diclofenac exposure during pregnancy increases the risk of low birth weight on fetus, increased risk of spontaneous abortion and increased risk of maternal vaginal bleeding. CONCLUSIONS Exposures to Diclofenac during pregnancy have adverse embryonic and maternal effect. So pregnant women taking Diclofenac may affect mother and fetus and additional primary RCTs are needed.


MedChemComm ◽  
2017 ◽  
Vol 8 (6) ◽  
pp. 1283-1296 ◽  
Author(s):  
Mohammed Amir Husain ◽  
Hassan Mubarak Ishqi ◽  
Tarique Sarwar ◽  
Sayeed Ur Rehman ◽  
Mohammad Tabish

Indomethacin belongs to the acetic acid derivative class of non-steroidal anti-inflammatory drugs with diverse pharmacological and biological activities.


2021 ◽  
Vol 7 (3) ◽  
pp. 64-72
Author(s):  
K. V. Tarapon ◽  
O. V. Tryhubchak

Aim. To analyze the range of prolonged-release dosage forms at the Ukrainian pharmaceutical market focusing on the pharmacotherapeutic groups that are insufficiently saturated with prolonged-release drugs, in particular to determine the proportion of non-steroidal anti-inflammatory drugs (NSAIDs). Materials and methods. The research was conducted in accordance with the data of the State Registry of Medicines of Ukraine and the АТС classification system. The methods of scientific analysis, in particular methods of grouping and comparison, marketing methods of analysis were applied. Results. The study of the assortment of prolonged-release drugs registered at the Ukrainian pharmaceutical market has been performed. The structure of the assortment by manufacturer, dosage forms, the АТС classification system has been analyzed. As a result of the study, it has been found that 202 trade names of prolonged-release drugs are registered in Ukraine. Most of them (196 names, 84 %) are medicines of foreign manufacturers. Prolonged-release drugs registered in Ukraine are mostly presented in the form of tablets and capsules, but tablets (72.77 %) are the largest part. The analysis of distribution of prolonged-release drugs by the ATC classification groups has shown that a significant number of prolonged-release drugs belongs to group N – Nervous system (80 trade names), and group C – Cardiovascular system (44 trade names). The share of group M – Musculoskeletal system, in particular prolonged-release NSAIDs, is insignificant (9 trade names). Conclusions. The marketing research of the prolonged-release drugs conducted allowed us to characterize the structure of the assortment of the Ukrainian market by pharmacotherapeutic groups, manufacturers and dosage forms. As a result of the research, the current assortment of prolonged-release NSAIDs has been determined.


2021 ◽  
Vol 9 (5) ◽  
pp. 400-409
Author(s):  
V. V. Prokopenko ◽  
T. I. Kabakova ◽  
M. V. Chernikov ◽  
A. B. Goryachev ◽  
S. A. Mikhailova ◽  
...  

the aim. Focused on optimizing the assortment portfolio of pharmacy organizations and improving the process of drug supply to end-consumers, the aim of the study was to analyze the regional pharmaceutical market for antihistamines.Materials and methods. In the study, the following methods were used: a content analysis of regulatory documents; a documentary observation method of the volume of antihistamines sales; a sociological survey method. The objects of the study were accounting registers in 32 pharmacy organizations for 2020, as well as the sociological survey results of 174 respondents – consumers of antihistamines.Results. The classification analysis of 38 international non-proprietary trade names of antihistamines, represented by 187 names of drugs, revealed the prevalence of the first-generation drugs (63%). On the Russian pharmaceutical market, there were also 55% of foreign production drugs. At the regional level, there are 66 types of drugs in circulation, 50% of which are second-generation ones. The cost analysis showed rather a wide rage of the pricing proposal and the economic availability of antihistamines for patients. The sociological survey revealed the fact that 46% of the consumers were ready to pay for the necessary drugs in the price range “over 100 and up to 500 rubles” (over $ 1.38 and up to $ 6.88) for one conventional package. A medical-demographic profile of the antihistamines consumer at the regional level has been made up, and guidelines for pharmaceutical specialists on managing the assortment portfolio of pharmaceutical organizations have been developed.Conclusion. As a result of the study, the following facts have been established: the seasonal peaks in the antihistamines consumption; a gradual renewal of the pharmacies assortment portfolio due to the increased consumption of the second and third generation antihistamines. The medical and demographic profile of the consumer should be taken into consideration when planning a drug provision for the patients with allergic pathologies, and it is connected with the growth in pharmacies profits due to the sale of drugs in the range from 100 to 500 rubles (from $ 1.38 to $ 6.88). The methodical recommendations have been brought to the attention of the management of regional pharmacy organizations.


2015 ◽  
Vol 17 (2) ◽  
Author(s):  
O. Ye. Yadlovskyi ◽  
А. Ya. Koval ◽  
N. M. Seredynska ◽  
T. A. Bukhtiarova ◽  
T. A. Bershova ◽  
...  

The search for new analgesic and anti-inflammatory drugs, exceeding by efficacy and/or safety the existing<br />analogues is very important and relevant. The nitrogenous heterocycles are promising in this respect, in particular,<br />the compounds containing an imidazole triazol and tіadiazin moiety. The aim of the current study was to investigate<br />the antiexudative and antinociceptive activity of new derivatives of 5,7-diacyl-3-H(alkyl)-6-aryl-5H[1,2,4]triazol[3,4-b]<br />[1,3,4]thiadiazine.<br />The antinociceptive and antiexudative activity studies were carried out on the white nonlinear mice. The<br />experimental evaluation of specific activity was carried out on the models “Hot plate”, acetic acid induced writhing<br />(antinociceptive action) and carrageenan edema (antiexudative action). The substance was used in a single oral rout<br />administration in a dose of 25 mg/kg. Ketorolac was used as a reference product in the dose of 25 mg/kg (models<br />“Hot plate”, acetic acid induced writhing). Diclofenac was used as a reference product in the dose of 25 mg/kg on<br />the model carrageenan edema. The experimental study showed the antinociceptive and antiexudative effects of the<br />derivatives. The antinociceptive activity of 5,7-diacyl-3-H(alkіl)-6-aryl-5H[1,2,4]triazol[3,4-b][1,3,4]tіadiazin derivaties<br />related to the modification structure in the para position of benzene ring. The antiexudative activity is associated with<br />acetyl groups thiadiazine ring. The most promising compound IFT_247 showed a significant antinociceptive effect,<br />which is comparable to an active comparator ketorolac: “Hot plate” +232.46 % and +112.71 %; acetic acid induced<br />writhing -66.67 % and -61.02 %, respectively.


Sign in / Sign up

Export Citation Format

Share Document